DURHAM, N.C., March 1, 2011 /PRNewswire/ — Chimerix, Inc., a
pharmaceutical company developing orally-available antiviral
therapeutics to address life-threatening diseases, announced today
that Kenneth I. Moch, President and Chief Executive Officer, will
present at the Cowen and Company 31st Annual Health Care Conference
on March 8, 2011, 1:30 pm ET, at the Boston Marriott Copley Place
in Boston, Massachusetts. The Cowen and Company Health Care
Conference is a conference for institutional investors focused on
private and emerging public life science companies.
Mr. Moch will give an update on the company’s pipeline and
technology assets, including CMX001, a broad-spectrum antiviral
being developed for the treatment of a wide range of infections
caused by double-stranded DNA (dsDNA) viruses. CMX001 is in Phase 2
clinical studies in immunocompromised transplant and cancer
patients for the prophylaxis and/or pre-emption of dsDNA viruses,
including BK virus and adenovirus. It is also undergoing an
Open-Label study for the treatment of patients with any of 12 dsDNA
infections which is designed to provide promising data for CMX001’s
fundamental studies. In addition, CMX001 is being developed
as a potential countermeasure in the event of a smallpox
release.
About Chimerix and CMX001
Chimerix is developing novel antiviral therapeutics with the
potential to transform patient care in multiple settings, including
transplant, oncology, acute care and global health.
The company’s lead candidate, CMX001, is being developed as a
potential broad spectrum antiviral agent for the treatment of
life-threatening double-stranded DNA (dsDNA) viral diseases. Over
350 people have received CMX001 to date, with a growing body of
evidence supporting the drug’s antiviral activity in humans.
Clinical studies of CMX001 include an ongoing Phase 2 study of
the prevention/control of cytomegalovirus (CMV) in hematopoietic
stem cell transplant p
‘/>”/>
